AU2016246134B2 - Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes - Google Patents

Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes Download PDF

Info

Publication number
AU2016246134B2
AU2016246134B2 AU2016246134A AU2016246134A AU2016246134B2 AU 2016246134 B2 AU2016246134 B2 AU 2016246134B2 AU 2016246134 A AU2016246134 A AU 2016246134A AU 2016246134 A AU2016246134 A AU 2016246134A AU 2016246134 B2 AU2016246134 B2 AU 2016246134B2
Authority
AU
Australia
Prior art keywords
igf
cells
odn
cancer
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2016246134A
Other languages
English (en)
Other versions
AU2016246134A1 (en
Inventor
David W. Andrews
Douglas C. Hooper
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Thomas Jefferson University
Original Assignee
Thomas Jefferson University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Thomas Jefferson University filed Critical Thomas Jefferson University
Publication of AU2016246134A1 publication Critical patent/AU2016246134A1/en
Assigned to THOMAS JEFFERSON UNIVERSITY reassignment THOMAS JEFFERSON UNIVERSITY Request for Assignment Assignors: ANDREWS, DAVID, HOOPER, DOUGLAS, THOMAS JEFFERSON UNIVERSITY
Application granted granted Critical
Publication of AU2016246134B2 publication Critical patent/AU2016246134B2/en
Priority to AU2022206776A priority Critical patent/AU2022206776B2/en
Priority to AU2025202730A priority patent/AU2025202730A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/7125—Nucleic acids or oligonucleotides having modified internucleoside linkage, i.e. other than 3'-5' phosphodiesters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/11—Antisense
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Reproductive Health (AREA)
  • Neurology (AREA)
  • Pulmonology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2016246134A 2015-04-10 2016-04-11 Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes Active AU2016246134B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2022206776A AU2022206776B2 (en) 2015-04-10 2022-07-21 Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
AU2025202730A AU2025202730A1 (en) 2015-04-10 2025-04-17 Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562145758P 2015-04-10 2015-04-10
US62/145,758 2015-04-10
PCT/US2016/026970 WO2016164916A1 (en) 2015-04-10 2016-04-11 Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2022206776A Division AU2022206776B2 (en) 2015-04-10 2022-07-21 Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes

Publications (2)

Publication Number Publication Date
AU2016246134A1 AU2016246134A1 (en) 2017-11-02
AU2016246134B2 true AU2016246134B2 (en) 2022-04-21

Family

ID=57072956

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2016246134A Active AU2016246134B2 (en) 2015-04-10 2016-04-11 Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
AU2022206776A Active AU2022206776B2 (en) 2015-04-10 2022-07-21 Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
AU2025202730A Pending AU2025202730A1 (en) 2015-04-10 2025-04-17 Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2022206776A Active AU2022206776B2 (en) 2015-04-10 2022-07-21 Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
AU2025202730A Pending AU2025202730A1 (en) 2015-04-10 2025-04-17 Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes

Country Status (8)

Country Link
US (6) US10206942B2 (https=)
EP (1) EP3280806A4 (https=)
JP (3) JP6957035B2 (https=)
CN (1) CN108260357A (https=)
AU (3) AU2016246134B2 (https=)
CA (1) CA2982205A1 (https=)
MX (2) MX386896B (https=)
WO (1) WO2016164916A1 (https=)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016164916A1 (en) 2015-04-10 2016-10-13 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes
CN108291227A (zh) 2015-10-14 2018-07-17 拜奥-帕斯控股股份有限公司 用于脂质体制剂的对乙氧基核酸
AU2017325971A1 (en) 2016-09-16 2019-04-11 Bio-Path Holdings, Inc. Combination therapy with liposomal antisense oligonucleotides
WO2018156725A1 (en) * 2017-02-24 2018-08-30 Thomas Jefferson University Methods and compositions for inhibiting tumor growth and enhancing immune responses to tumors
US10357509B2 (en) 2017-03-09 2019-07-23 Thomas Jefferson University Methods and compositions for treating cancers using antisense
EA201992485A1 (ru) 2017-04-19 2020-02-17 Байо-Пат Холдингз, Инк. Р-этокси нуклеиновые кислоты для ингибирования stat3
CA3060090A1 (en) * 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for igf-1r inhibition
AU2018255353B2 (en) * 2017-04-19 2023-11-16 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for IGF-1R inhibition
EA201992490A1 (ru) 2017-04-19 2020-03-03 Байо-Пат Холдингз, Инк. Р-этокси нуклеиновые кислоты для ингибирования bcl2
JP2020528077A (ja) * 2017-07-14 2020-09-17 ミンジェン シュー， Ｍ１優位の免疫応答を誘導するための方法および薬学的組成物
GB201714330D0 (en) 2017-09-06 2017-10-18 Järver Peter Oligonucleotides
CA3089583A1 (en) * 2018-01-24 2019-08-01 Thomas Jefferson University Biodiffusion chamber
EP3873497A4 (en) * 2018-11-02 2022-08-03 Thomas Jefferson University METHODS AND COMPOSITIONS FOR THE TREATMENT OF BREAST CANCER USING ANTISENSE NUCLEIC ACIDS
AU2019374061A1 (en) * 2018-11-02 2021-06-03 Thomas Jefferson University Methods and compositions for treating hepatocellular carcinoma using antisense
MX2021011760A (es) * 2019-03-28 2021-12-10 Univ Jefferson Metodos para el tratamiento de canceres usando antisentido.
USD1107915S1 (en) 2019-07-23 2025-12-30 Thomas Jefferson University Biodiffusion chamber

Family Cites Families (85)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK114394B (da) 1963-06-17 1969-06-23 O Hoyer Fremgangsmåde ved emballering af aflange formlegemer, navnlig ispinde, samt maskine til udøvelse af fremgangsmåden.
US3331526A (en) 1964-07-20 1967-07-18 Levenson Leonard Lionel Ultrahigh vacuum seal
US3270877A (en) 1965-06-18 1966-09-06 Hanns E Hecker Package for columnar articles
US3589511A (en) 1969-08-13 1971-06-29 Owens Illinois Inc Package and tray for tubes or the like
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5583024A (en) 1985-12-02 1996-12-10 The Regents Of The University Of California Recombinant expression of Coleoptera luciferase
EP0247730A3 (en) 1986-04-28 1989-04-12 Antibody Technology Limited Antibodies, their preparation and use and products containing them
US5167638A (en) 1989-10-27 1992-12-01 C. R. Bard, Inc. Subcutaneous multiple-access port
US5834005A (en) 1992-02-24 1998-11-10 Encelle, Inc. Bioartificial devices and cellular matrices therefor
EP0750516A4 (en) * 1993-03-26 1998-07-01 Univ Jefferson METHOD FOR INHIBITING CELL PROLIFERATION AND TRIGGERING CELL DIFFERENTIATION USING TYPE 1 GROWTH FACTOR RECEPTOR OLIGONUCLEOTIDES
US6340674B1 (en) 1993-03-26 2002-01-22 Thomas Jefferson University Method of inhibiting the proliferation and causing the differentiation of cells with IGF-1 receptor antisense oligonucleotides
US6214345B1 (en) 1993-05-14 2001-04-10 Bristol-Myers Squibb Co. Lysosomal enzyme-cleavable antitumor drug conjugates
EP0647450A1 (en) 1993-09-09 1995-04-12 BEHRINGWERKE Aktiengesellschaft Improved prodrugs for enzyme mediated activation
US5714170A (en) 1994-11-16 1998-02-03 Thomas Jefferson University Method of inducing resistance to tumor growth
JPH08336393A (ja) 1995-04-13 1996-12-24 Mitsubishi Chem Corp 光学活性なγ−置換−β−ヒドロキシ酪酸エステルの製造法
US6218519B1 (en) 1996-04-12 2001-04-17 Pro-Neuron, Inc. Compounds and methods for the selective treatment of cancer and bacterial infections
EP0961619A4 (en) 1996-09-27 2001-09-26 Bristol Myers Squibb Co HYDROLYSABLE DRUGS FOR THE RELEASE OF ANTI-CANCER DRUGS IN METASTATIC CELLS
US6759509B1 (en) 1996-11-05 2004-07-06 Bristol-Myers Squibb Company Branched peptide linkers
US6071891A (en) 1996-11-22 2000-06-06 Regents Of The University Of Minnesota Insulin-like growth factor 1 receptors (IGF-1R) antisense oligonucleotide cells composition
US6541036B1 (en) 1997-05-29 2003-04-01 Thomas Jefferson University Treatment of tumors with oligonucleotides directed to insulin-like growth factor-I receptors (IGF-IR)
US6602677B1 (en) 1997-09-19 2003-08-05 Promega Corporation Thermostable luciferases and methods of production
HK1040052B (zh) 1998-05-22 2006-09-15 第一制药株式会社 药物复合物
JP2002522506A (ja) * 1998-08-13 2002-07-23 トーマス・ジェファーソン・ユニバーシティ インスリン様増殖因子−ｉ受容体に向けられるオリゴヌクレオチドを用いた腫瘍の処置
GB9818731D0 (en) 1998-08-27 1998-10-21 Univ Portsmouth Compounds
US6144553A (en) 1998-09-09 2000-11-07 Sun Microsystems, Inc. Refrigeration cooled disk storage assembly
US6268488B1 (en) 1999-05-25 2001-07-31 Barbas, Iii Carlos F. Prodrug activation using catalytic antibodies
IL134009A (en) 2000-01-12 2011-07-31 Bo2 Technologies Ltd Transplant device
US20040052793A1 (en) 2001-02-22 2004-03-18 Carter Paul J. Caspase activivated prodrugs therapy
WO2002027019A1 (en) 2000-09-29 2002-04-04 The Johns Hopkins University School Of Medicine Method of predicting the clinical response to chemotherapeutic treatment with alkylating agents
US20040018194A1 (en) 2000-11-28 2004-01-29 Francisco Joseph A. Recombinant anti-CD30 antibodies and uses thereof
EP1243276A1 (en) 2001-03-23 2002-09-25 Franciscus Marinus Hendrikus De Groot Elongated and multiple spacers containing activatible prodrugs
US6884869B2 (en) 2001-04-30 2005-04-26 Seattle Genetics, Inc. Pentapeptide compounds and uses related thereto
WO2003026577A2 (en) 2001-09-24 2003-04-03 Seattle Genetics, Inc. P-amidobenzylethers in drug delivery agents
US7091186B2 (en) 2001-09-24 2006-08-15 Seattle Genetics, Inc. p-Amidobenzylethers in drug delivery agents
CA2467242A1 (en) 2001-11-20 2003-05-30 Seattle Genetics, Inc. Treatment of immunological disorders using anti-cd30 antibodies
AU2003294210A1 (en) 2002-07-31 2004-05-04 Seattle Genetics, Inc Anti-cd20 antibody-drug conjugates for the treatment of cancer and immune disorders
AU2003256038A1 (en) 2002-08-30 2004-03-19 Ramot At Tel Aviv University Ltd. Self-immolative dendrimers releasing many active moieties upon a single activating event
JP2006507322A (ja) 2002-11-14 2006-03-02 シンタルガ・ビーブイ 多重自己脱離放出スペーサーとして構築されたプロドラッグ
US7037335B2 (en) 2002-11-19 2006-05-02 Eagle Vision, Inc. Bulbous scleral implants for the treatment of eye disorders such as presbyopia and glaucoma
WO2004072284A1 (en) 2003-02-11 2004-08-26 Antisense Therapeutics Ltd Modulation of insulin like growth factor i receptor expression
US7846906B2 (en) 2003-02-28 2010-12-07 Isis Pharmaceuticals, Inc. Modulation of growth hormone receptor expression and insulin-like growth factor expression
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
CA2447400A1 (en) 2003-09-12 2005-03-12 The Hospital For Sick Children Brain tumor stem cells
EP2905033B1 (en) 2003-12-16 2020-09-02 Nektar Therapeutics Monodisperse PEGylated naloxol compositions
EP1720908A2 (en) 2004-02-17 2006-11-15 Absalus, Inc. Super-humanized antibodies against respiratory syncytial virus
EP1718667B1 (en) 2004-02-23 2013-01-09 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
US7361168B2 (en) 2004-04-21 2008-04-22 Acclarent, Inc. Implantable device and methods for delivering drugs and other substances to treat sinusitis and other disorders
KR101270829B1 (ko) 2004-09-23 2013-06-07 제넨테크, 인크. 시스테인 유전자조작 항체 및 접합체
NZ554831A (en) 2004-11-09 2009-10-30 Schering Corp Improved dosing regimen of temozolomide for treating cancer based on the patientÆs MGMT level
ES2417133T3 (es) 2005-02-03 2013-08-06 Antitope Limited Anticuerpos y proteínas humanas
HRP20110498T1 (hr) 2005-10-07 2011-08-31 Exelixis Azetidini kao inhibitori mek za liječenje proliferativnih bolesti
SI1813614T1 (sl) 2006-01-25 2012-01-31 Sanofi 174 Citotoksična sredstva, ki obsegajo nove tomajmicinske derivate
EP1900825A1 (en) 2006-09-13 2008-03-19 Rheinische Friedrich-Wilhelms-Universität Bonn Sensitive and reproducible method for the determination of MGMT promoter methylation in clinical samples
EP2144628B1 (en) 2007-05-08 2012-10-17 Genentech, Inc. Cysteine engineered anti-muc16 antibodies and antibody drug conjugates
MX2010003718A (es) 2007-10-19 2010-04-21 Genentech Inc Anticuerpos anti-tenb2 producidos por ingenieria de cisteina y conjugados de farmaco y anticuerpo.
DK2240155T3 (da) 2008-02-13 2012-09-17 Intarcia Therapeutics Inc Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
US9446168B2 (en) 2010-06-07 2016-09-20 Beta-O2 Technologies Ltd. Multiple-layer immune barrier for donor cells
GB0819095D0 (en) 2008-10-17 2008-11-26 Spirogen Ltd Pyrrolobenzodiazepines
FI123146B (fi) 2009-10-01 2012-11-30 Bayer Schering Pharma Oy Kohdunsisäinen järjestelmä
CA2783665A1 (en) 2010-03-03 2011-09-09 OSI Pharmaceuticals, LLC Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors
DK2528625T3 (da) 2010-04-15 2013-10-14 Spirogen Sarl Pyrrolobenzodiazepiner og konjugater deraf
US8697688B2 (en) 2010-04-15 2014-04-15 Seattle Genetics Inc. Pyrrolobenzodiazepines used to treat proliferative diseases
WO2011130615A2 (en) 2010-04-15 2011-10-20 Dr. Reddy's Laboratories Ltd. Preparation of lacosamide
MX391454B (es) 2010-04-15 2025-03-05 Seagen Inc Compuesto de engarce-fármaco para conjugación a una unidad de ligando.
CA2812707C (en) 2010-09-27 2020-02-18 Gloriana Therapeutics Sarl Implantable cell device with supportive and radial diffusive scaffolding
ES2677070T3 (es) 2010-10-27 2018-07-27 Curna, Inc. Tratamiento de enfermedades relacionadas con el regulador del desarrollo 1 asociado a interferón (ifrd1) mediante inhibición del transcrito antisentido natural al gen ifrd1
EP2567905A1 (en) 2011-09-09 2013-03-13 Becton Dickinson France Tray and packaging for medical containers
JP2015521602A (ja) 2012-06-14 2015-07-30 アンブルックス, インコーポレイテッドAmbrx, Inc. 核受容体リガンドポリペプチドに対して複合化されている抗ｐｓｍａ抗体
CN102898426B (zh) * 2012-11-15 2015-04-22 江苏先声药业有限公司 抑制igf-1r酪氨酸激酶活性的吡啶并吡唑类衍生物
EP2988699B1 (en) 2013-04-24 2020-05-27 Société des Produits Nestlé S.A. Encapsulation device
US9539757B2 (en) 2013-06-26 2017-01-10 Tekni-Plex, Inc. Packing tray having cell pockets with expandable sidewalls and floating base, and method of manufacture
WO2015035365A1 (en) 2013-09-09 2015-03-12 The Nohns Hopkins University Targeting the m2-tumor associated macrophage for cancer therapy
CN105792775B (zh) 2013-09-24 2019-02-19 吉纳生命科学公司 用于细胞植入物的气体处理的系统
AU2014375206B2 (en) 2014-01-03 2021-09-30 Innosign B.V. Assessment of the PI3K cellular signaling pathway activity using mathematical modelling of target gene expression.
US9872674B2 (en) 2014-05-07 2018-01-23 Boehringer Laboratories Inc. Entrapment and containment system for use with a morcellator and method of entrapping and containing material produced during morcellation procedure
WO2016164916A1 (en) 2015-04-10 2016-10-13 Thomas Jefferson University Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory m2 monocytes
CA3250034A1 (en) 2015-04-23 2025-10-30 Applied Medical Resources Corporation Systems and methods for tissue removal
ES2887273T3 (es) 2015-06-29 2021-12-22 Immunogen Inc Anticuerpos anti-CD123 y conjugados y derivados de los mismos
CN108291227A (zh) 2015-10-14 2018-07-17 拜奥-帕斯控股股份有限公司 用于脂质体制剂的对乙氧基核酸
US10357509B2 (en) * 2017-03-09 2019-07-23 Thomas Jefferson University Methods and compositions for treating cancers using antisense
CA3060090A1 (en) 2017-04-19 2018-10-25 Bio-Path Holdings, Inc. P-ethoxy nucleic acids for igf-1r inhibition
CA3089583A1 (en) 2018-01-24 2019-08-01 Thomas Jefferson University Biodiffusion chamber
EP4031465B1 (en) 2019-09-19 2026-01-28 Thomas Jefferson University Apparatus and methods for biodiffusion chamber storage
CA3171914A1 (en) 2020-03-18 2021-09-23 Vincent Ling Implantable cell chamber device and uses thereof
JP2023521400A (ja) 2020-04-09 2023-05-24 デファイメッド 医療デバイス用の膜

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
DAVID W. ANDREWS ET AL, JOURNAL OF CLINICAL ONCOLOGY, US, (2001-04-15), vol. 19, no. 8, doi:10.1200/JCO.2001.19.8.2189, ISSN 0732-183X, pages 2189 - 2200 *
HARSHYNE LARRY A ET AL, CANCER IMMUNOLOGY, IMMUNOTHERAPY, SPRINGER, BERLIN/HEIDELBERG, vol. 64, no. 3, doi:10.1007/S00262-014-1622-Z, ISSN 0340-7004, (2014-11-14), pages 299 - 309, (2014-11-14) *

Also Published As

Publication number Publication date
AU2022206776B2 (en) 2025-05-08
JP2021193143A (ja) 2021-12-23
MX386896B (es) 2025-03-19
US10265339B2 (en) 2019-04-23
US20170056430A1 (en) 2017-03-02
AU2025202730A9 (en) 2026-03-05
MX2017012982A (es) 2018-07-06
CA2982205A1 (en) 2016-10-13
US20200197435A1 (en) 2020-06-25
EP3280806A1 (en) 2018-02-14
US10206942B2 (en) 2019-02-19
EP3280806A4 (en) 2018-12-05
CN108260357A (zh) 2018-07-06
US20180235996A1 (en) 2018-08-23
US20220072025A1 (en) 2022-03-10
MX2021012272A (es) 2021-11-12
JP2018515598A (ja) 2018-06-14
WO2016164916A1 (en) 2016-10-13
AU2016246134A1 (en) 2017-11-02
US11077133B2 (en) 2021-08-03
US12064446B2 (en) 2024-08-20
AU2022206776A1 (en) 2022-09-15
US20250009781A1 (en) 2025-01-09
US20180271894A1 (en) 2018-09-27
JP7428397B2 (ja) 2024-02-06
JP6957035B2 (ja) 2021-11-02
AU2025202730A1 (en) 2025-05-08
JP2024028529A (ja) 2024-03-04
US10543226B2 (en) 2020-01-28

Similar Documents

Publication Publication Date Title
AU2022206776B2 (en) Methods and compositions for treating cancers and enhancing therapeutic immunity by selectively reducing immunomodulatory M2 monocytes
Ribas et al. Overcoming PD-1 blockade resistance with CpG-A toll-like receptor 9 agonist vidutolimod in patients with metastatic melanoma
AU2018230458B2 (en) Methods and compositions for treating cancers using antisense
Schäkel et al. Human 6-sulfo LacNAc-expressing dendritic cells are principal producers of early interleukin-12 and are controlled by erythrocytes
US20240262909A1 (en) Tim-3 modulates anti-tumor immunity by regulating inflammasome activation
JP2024521514A (ja) がん治療のための順次的な自然免疫調節と適応免疫調節
HK40112216A (en) Methods and compositions for treating cancers using antisense
HK40022361A (en) Compositions for treating cancers using antisense
HK40022361B (en) Compositions for treating cancers using antisense
Ribas et al. Overcoming PD-1 Blockade Resistance With CpG-A Toll-Like Receptor 9 Agonist Vidutolimod in Patients With Metastatic Melanoma (125/165 characters [incl spaces])

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: THOMAS JEFFERSON UNIVERSITY

Free format text: FORMER APPLICANT(S): HOOPER, DOUGLAS; ANDREWS, DAVID; THOMAS JEFFERSON UNIVERSITY

FGA Letters patent sealed or granted (standard patent)